Do antioxidants interfere with radiation therapy for cancer?

Integrative Cancer Therapies

Volumn 6, Issue 3, 2007, Pages 281-292

  Moss, Ralph W ^a  

^a Cancer Communications Inc   (United States)

Author keywords

tocopherol; Amifostine; Antioxidants; Chemotherapy; Free radicals; Melatonin; Pentoxifylline; Radiation; Radiotherapy; Retinol palmitate; Vitamins

Indexed keywords

ALPHA TOCOPHEROL; AMIFOSTINE; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FREE RADICAL; GREEN TEA EXTRACT; IFOSFAMIDE; MELATONIN; MESNA; MEXNEX; MULTIVITAMIN; NICOTINAMIDE; PENTOXIFYLLINE; PLACEBO; RAZOXANE; RETINOL PALMITATE; SELENIUM; UNCLASSIFIED DRUG;

ADD ON THERAPY; ALTERNATIVE MEDICINE; BONE NECROSIS; BRAIN CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; DIARRHEA; DIETARY INTAKE; DRUG EFFECT; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; FECES INCONTINENCE; FIBROSIS; GLIOBLASTOMA; HEAD AND NECK CANCER; HEART PROTECTION; HEMORRHAGIC CYSTITIS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MOUTH CANCER; MUCOSA INFLAMMATION; NEPHROTOXICITY; OVARY CANCER; OXIDATIVE STRESS; PAIN; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION; RADIATION DOSE; RADIATION INJURY; RADIATION PROTECTION; RECTUM DISEASE; REVIEW; SOFT TISSUE SARCOMA; TENESMUS; TREATMENT RESPONSE; TRISMUS; UTERINE CERVIX CANCER; XEROSTOMIA;

ANTIOXIDANTS; COMBINED MODALITY THERAPY; COMPLEMENTARY THERAPIES; HUMANS; NEOPLASMS; RADIOTHERAPY; TREATMENT OUTCOME;

EID: 34548134503     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735407305655     Document Type: Review

References (61)

1. D'Andrea GM Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J Clin. 2005 ; 55: 319-321.
2. Parker-Pope T. Cancer and vitamins: patients urged to avoid supplements during treatment. The Wall Street Journal. Sept 20, 2005: D:1.
3. Conklin KA Dietary antioxidants during cancer chemotherapy: impact on chemotherapeutic effectiveness and development of side effects. Nutr Cancer. 2000 ; 37: 1-18.
4. Cameron NE, Cotter MA Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Res Clin Pract. 1999 ; 45: 137-146.
5. Conklin KA Cancer chemotherapy and antioxidants. J Nutr. 2004 ; 34: 3201S - 3204S.
6. National Institutes of Health (NIH). Free Radicals: The Pros and Cons of Antioxidants. Masur Auditorium, NIH Campus Bethesda, Md, June 26-27, 2003. http://www.cancer.gov/prevention/frpca2003/summary.html. Accessed June 11, 2007
7. Prasad KN, Cole WC, Kumar B., Che Prasad K. Pros and cons of antioxidant use during radiation therapy. Cancer Treat Rev. 2002 ; 28: 79-91.
8. Block KI, Koch AC, Mead MN, Tothy PK, Newman RA, Gyllenhaal C. Impact of antioxidant supplementation on chemotherapeutic efficacy: A systematic review of the evidence from randomized controlled trials. Cancer Treat Rev. 2007 Mar 14; [Epub ahead of print]
9. Simone CB II, Simone NL, Simone V., Simone CB Antioxidants and other nutrients do not interfere with chemotherapy or radiation therapy and can increase kill and increase survival, part 1. Altern Ther Health Med. 2007 ; 13: 22-28.
10. Moss, RW Antioxidants Against Cancer. Brooklyn, NY: Equinox Press ; 2000.
11. Moss RW Should patients undergoing chemotherapy and radiotherapy be prescribed antioxidants? Integr Cancer Ther. 2006 ; 5: 63-82.
12. Bairati I., Meyer F., Gelinas M., et al. Randomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol. 2005 ; 23: 5805-5813.
13. Bairati I., Meyer F., Gelinas M., et al. A randomized trial of antioxidant vitamins to prevent second primary cancers in head and neck cancer patients. J Natl Cancer Inst. 2005 ; 97: 481-488.
14. Bairati I., Meyer F., Jobin E., et al. Antioxidant vitamins supplementation and mortality: a randomized trial in head and neck cancer patients. Int J Cancer. 2006 ; 119: 2221-2224.
15. Weijl NI, Cleton FJ, Osanto S. Free radicals and antioxidants in chemotherapy-induced toxicity. Cancer Treat Rev. 1997 ; 23: 209-240.
16. Sangeetha P., Das UN, Koratkar R., Suryaprabha P. Increase in free radical generation and lipid peroxidation following chemotherapy in patients with cancer. Free Radic Biol Med. 1990 ; 8: 15-19.
17. Durken M., Agbenu J., Finckh B., et al. Deteriorating free radical-trapping capacity and antioxidant status in plasma during bone marrow transplantation. Bone Marrow Transplant. 1995 ; 15: 757-762.
18. Lauterburg BH, Nguyen T., Hartmann B., Junker E., Kupfer A., Cerny T. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol. 1994 ; 35: 132-136.
19. Koh E-S., Tran TH, Heydarian M., et al. A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol. 2007 ; 2: 13.
20. Galloway D. Treating patients with cancer requires looking beyond the tumor. OncoLog. 2004 ; 49 :No. 7-8. http://www.2.mdanderson.org/depts/oncolog/ articles/04/7-8-julaug/7-8-04-3.html. Accessed May 24, 2007.
21. Clemens MR, Ladner C., Schmidt H., et al. Decreased essential antioxidants and increased lipid hydroperoxides following high-dose radiochemotherapy. Free Radic Res Commun. 1989 ; 7: 227-232.
22. Jonas CR, Puckett AB, Jones DP, et al. Plasma antioxidant status after high-dose chemotherapy: a randomized trial of parenteral nutrition in bone marrow transplantation patients. Am J Clin Nutr. 2000 ; 72: 181-189.
23. Lin JQ Effect of nutrition intervention on antioxidant capacity and lipid peroxide in patients with bone marrow transplantation. Di Yi Jun Yi Da Xue Xue Bao. 2002 ; 22: 530-532.
24. Bhuvarahamurthy V., Balasubramanian N., Govindasamy S. Effect of radiotherapy and chemoradiotherapy on circulating antioxidant system of human uterine cervical carcinoma. Mol Cell Biochem. 1996 ; 158: 17-23.
25. Elango N., Samuel S., Chinnakkannu P. Enzymatic and non-enzymatic antioxidant status in stage (III) human oral squamous cell carcinoma and treated with radical radio therapy: influence of selenium supplementation. Clin Chim Acta. 2006 ; 373: 92-98.
26. Ferreira PR, Fleck JF, Diehl A., et al. Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck. 2004 ; 26: 313-321.
27. Horvath B., Marton Z., Halmosi R., et al. In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin Neuropharmacol. 2002 ; 25: 37-42.
28. Delanian S., Porcher R., Rudant J., Lefaix JL Kinetics of response to long-term treatment combining pentoxifylline and tocopherol in patients with superficial radiation-induced fibrosis. J Clin Oncol. 2005 ; 23: 8570-8579.
29. Delanian S., Lefaix JL Current management for late normal tissue injury: radiation-induced fibrosis and necrosis. Semin Radiat Oncol. 2007 ; 17: 99-107.
30. Delanian S., Depondt J., Lefaix JL Major healing of refractory mandible osteoradionecrosis after treatment combining pentoxifylline and tocopherol: a phase II trial. Head Neck. 2005 ; 27: 114-123.
31. Letur-Konirsch H., Guis F., Delanian S. Uterine restoration by radiation sequelae regression with combined pentoxifylline-tocopherol: a phase II study. Fertil Steril. 2002 ; 77: 1219-1226.
32. Chua D., Lo C., Yuen J., Foo YC A pilot study of pentoxifylline in the treatment of radiation-induced trismus. Am J Clin Oncol. 2001 ; 24: 366-369.
33. Lee I., Kim JH, Levitt SH, Song CW Increases in tumor response by pentoxifylline alone or in combination with nicotinamide. Int J Radiat Oncol Biol Phys. 1992 ; 22: 425-429.
34. Ozturk B., Egehan I., Atavci S., Kitapci M. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: a double-blind randomized trial. Int J Radiat Oncol Biol Phys. 2004 ; 58: 213-219.
35. Kwon HC, Kim SK, Chung WK, et al. Effect of pentoxifylline on radiation response of non-small cell lung cancer: a phase III randomized multicenter trial. Radiother Oncol. 2000 ; 56: 175-179.
36. Misirlioglu CH, Erkal H., Elgin Y., Ugur I., Altundag K. Effect of concomitant use of pentoxifylline and alpha-tocopherol with radiotherapy on the clinical outcome of patients with stage IIIB non-small cell lung cancer: a randomized prospective clinical trial. Med Oncol. 2006 ; 23: 185-189.
37. Lissoni P., Meregalli S., Nosetto L., et al. Increased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology. 1996 ; 53: 43-46.
38. Ehrenpreis ED, Jani A., Levitsky J., Ahn J., Hong J. A prospective, randomized, double-blind, placebo-controlled trial of retinol palmitate (vitamin A) for symptomatic chronic radiation proctopathy. Dis Colon Rectum. 2005 ; 48: 1-8.
39. Rex, Douglas K. Vitamin A reduces nonbleeding symptoms of chronic radiation proctopathy. Journal Watch Gastroenterology, April 12, 2005. http://gastroenterology.jwatch.org/cgi/content/full/2005/412/1. Accessed June 11, 2007.
40. Birdsall TC, Alschuler LN, Martin J., et al. Effect of concomitant naturopathic therapies on clinical tumor response to external beam radiation therapy for prostate cancer. Abstract presented at: Society for Integrative Oncology ; November 2006 ; Boston, Mass.
41. Cain L., Flynn J., Kelly D., et al. Effect of complementary alternative medical (CAM) therapy on tumor response, control and recurrence in prostate cancer patients (PCpts) treated with radiation therapy (RT). J Clin Oncol. 2007 ; 25: 15585.
42. Jaakkola K., Lahteenmaki P., Laakso J., Harju E., Tykka H., Mahlberg K. Treatment with antioxidant and other nutrients in combination with chemotherapy and irradiation in patients with small-cell lung cancer. Anticancer Res. 1992 ; 12: 599-606.
43. Marzatico F., Porta C., Moroni M., et al. In vitro antioxidant properties of amifostine (WR-2721, Ethyol). Cancer Chemother Pharmacol. 2000 ; 45: 172-176.
44. Hensley ML, Schuchter LM, Lindley C., et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999 ; 17: 3333-3355.
45. Capizzi RL Clinical status and optimal use of Amifostine. Oncology (Willison Park). 1993 ; 13: 47-59.
46. Kemp G., Rose P., Lurain J., et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol. 1996 ; 14: 2101-2112.
47. Food and Drug Administration (FDA). Oncology Division Advisory Committee (ODAC). Fulfillment of the accelerated approval requirements for the non-small cell lung cancer indication: ethyol (Amifostine) reduces the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced non-small cell lung cancer. http://www.fda.gov/ohrms/dockets/ac/03/ briefing/3936B1_05_MedImmune-Eythol.htm. Accessed March 2007.
48. Anne PR, Machtay M., Rosenthal DI, et al. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2007 ; 67: 445-452.
49. Andreassen CN, Grau C., Lindegaard JC Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy. Sem Radiat Oncol. 2003 ; 13: 62-72.
50. Mell LK, Malik R., Komaki R., et al. Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis, Int J Radiat Oncol Biol Phys. 2007 ; 68: 111-118.
51. Antonadou D., Pepelassi M., Synodinou M., Puglisi M., Throuvalas N. Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Bio Phys. 2002 ; 52: 739-747.
52. Rhomberg W., Hassenstein EO, Gefeller D. Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study. Int J Radiat Oncol Biol. 1996 ; 36: 1077-1084.
53. Moghrabi A., Levy DE, Asselin B., et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood. 2007 ; 109: 896-904.
54. Dechant KL, Brogden RN, Pilkington T., Faulds D. Ifosfamide/ mesna: a review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs. 1991 ; 42: 428-467.
55. National Institute of Health, National Library of Medicine. DailyMed: Drug Package Labels, "mesna." http://dailymed.nlm.nih.gov/dailymed/ drugList.cfm?startswith=M. Accessed May 24, 2007.
56. Becher R., Kakati S., Gibas Z., Sandberg AA Cytogenetic testing of mutagenic and radioprotective effects of mesna. Oncology. 1983 ; 40: 287-289.
57. Kangarloo SB, Gangopadhyay SB, Syme RM, Wolff Jea, Gluck S. Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients. Med Oncol. 2004 ; 21: 9-20.
58. Kumar L., Kaushal R., Nandy M., et al. Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study. Gynecol Oncol. 1994 ; 54: 307-315.
59. Camphausen K., Citrin D., Krishna MC, Mitchell JB Implications for tumor control during protection of normal tissues with antioxidants. J Clin Oncol. 2005 ; 23: 5455-5477.
60. Block K. Antioxidants in the news. Integr Cancer Ther. 2005 ; 4: 271-273.
61. Safety of Oral Antioxidants and Intravenous Vitamin C During GYN Cancer Care." http://clinicaltrials.gov/ct/show/NCT00284427. Accessed May 24, 2007.